The waiting game Nothing happens quickly in the world of biotech, and from an investor point of view this can be the toughest part. For shareholders in Melbourne based stem cell company, Mesoblast, the waiting game has been excruciating. As the world ground to a halt due to the Read more…
Happy New Year? January looms as a crucial month for the near-term prospects of Australian biotech, Mesoblast. December saw the company’s treatments fail to meet primary endpoints in both its Chronic Heart Failure (CHF) and COVID-19 Acute Respiratory Distress Syndrome (C19 ARDS) phase 3 trials. These failures, along with Read more…
Mesoblasted ! 22/12/2020 In a tumultuous few days for biotech hopeful, Mesoblast, a series of poor results has seen the share price smashed down by over 50% in less than a week. This all came on top an earlier failure by Mesoblast to gain approval for their treatment for Read more…
Novartis Partnership The prospect has taken up countless column inches in various newspapers and web forums over the years but today Mesoblast has finally found itself a tier one pharma company to collaborate on its promising treatment for inflammatory diseases, remestemcel-L. The Swiss major, Novartis has entered into an exclusive Read more…
Body blow Last Friday the US Food and Drug Administration (FDA) delivered a body blow to the near-term ambitions of Australian biotech hopeful, Mesoblast, with its decision to issue a Complete Response Letter (CRL) for the company’s treatment for pediatric patients with steroid-refractory graft versus host disease (GVHD), Remestemcel-L. Read more…
Stem Cells This article was from way back in June and is an absolute ripper. The author of the story has obviously done his research as evidenced by the in depth coverage. There’s great coverage for followers of both Mesoblast and Athersys. Some of you may have seen this article Read more…
No surprises. The decision by the independent Data Safety Monitoring Board (DSMB) to continue Mesoblasts 300-patient clinical trial into Covid-19 ARDS was entirely as anticipated. The independent DSMB are the only people allowed to check the data produced by the trial and despite some people’s opinions I’ve heard, they Read more…
Fasten your seatbelts! You’d be hard pressed to find a biotech company anywhere in the world with a more exciting calendar than Mesoblast in the next two months. Front and center is the lead product candidate Remestemcel-L, or Ryoncil. Not later than September 30th, the FDA will decide whether Read more…
The calm before the storm ? The next 2 weeks are likely to be a little more subdued in the lead-up, to what should be an incredibly busy September for Mesoblast. FDA approval for RYONCIL appears close to certain, this will likely happen earlier than the 30th of September cut Read more…
What a week it’s been for Mesoblast shareholders. The week had a promising start with a healthy gain on Monday on optimism around the upcoming ODAC meeting which was to review MSB’s data supporting the BLA for its treatment for SR-aGVHD, RYONCIL. Late on Monday night/Tuesday morning, the FDA released Read more…